A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Latest Information Update: 02 Feb 2026
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CLEAR
Most Recent Events
- 30 Jan 2026 Status changed from recruiting to suspended.
- 10 Jul 2025 Planned initiation date changed from 13 Jun 2025 to 10 Mar 2026.
- 10 Jul 2025 Status changed from not yet recruiting to recruiting.